RSV Vaccine Study
The purpose of the study is to determine safety, tolerability, and immunogenicity of an RSV vaccine in health older adults. Respirator syncytial virus, or RSV, usually causes mild, cold-like symptoms, but can lead to serious illness, especially for infants or older adults. RSV can cause severe lung infections, including bronchiolitis and pneumonia. The study will last up to 13 months with up to 7 clinic visits. Qualified participants will receive study-related care and vaccination, or placebo, at no cost, and may be compensated for study-related time and travel.
Male and Female
Why take part?
Participants will receive study-related doctor’s care, study medication at no cost. Compensation for study-related time and travel may be available.Millions of people lack the treatment they need to manage their conditions. As one of the largest and most recognized clinical study organisations in the world, Synexus provides a friendly relaxed environment where you have the opportunity to help others and maybe also yourself.
Who is Synexus?
Synexus is a company dedicated to conducting clinical studies, and has been investigating the effectiveness of new study drugs and treatments for more than 20 years. We provide a friendly, relaxed environment in our own clinics where you have the chance to help shape the future of health for yourself and for others.We are sure you probably have more questions about the study, and we would be happy to take the time to give you more details.
All Synexus studies are approved by an independent ethics committee.